Trial Profile
Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Pharmacokinetics
- 26 Sep 2021 Status changed from recruiting to completed.
- 28 Sep 2018 New trial record